APA (7th ed.) Citation

Tan, C., Li, S., Yi, L., Zeng, X., Peng, L., Qin, S., . . . Wan, X. (2021). Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. Advances in therapy, 38(5), 2571-2585. https://doi.org/10.1007/s12325-021-01733-7

Chicago Style (17th ed.) Citation

Tan, Chongqing, Sini Li, Lidan Yi, Xiaohui Zeng, Liubao Peng, Shuxia Qin, Liting Wang, and Xiaomin Wan. "Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population." Advances in Therapy 38, no. 5 (2021): 2571-2585. https://doi.org/10.1007/s12325-021-01733-7.

MLA (9th ed.) Citation

Tan, Chongqing, et al. "Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population." Advances in Therapy, vol. 38, no. 5, 2021, pp. 2571-2585, https://doi.org/10.1007/s12325-021-01733-7.